Your browser is no longer supported. Please, upgrade your browser.
ATHX [NASD]
Athersys, Inc.
Index- P/E- EPS (ttm)-0.42 Insider Own1.80% Shs Outstand198.37M Perf Week-7.78%
Market Cap333.46M Forward P/E- EPS next Y-0.10 Insider Trans-1.89% Shs Float178.83M Perf Month-19.37%
Income-78.80M PEG- EPS next Q-0.10 Inst Own25.70% Short Float14.55% Perf Quarter-43.38%
Sales1.40M P/S238.18 EPS this Y-43.00% Inst Trans-0.32% Short Ratio9.84 Perf Half Y-14.92%
Book/sh0.16 P/B9.62 EPS next Y70.60% ROA-124.00% Target Price- Perf Year-41.44%
Cash/sh0.24 P/C6.47 EPS next 5Y- ROE-198.50% 52W Range1.51 - 3.39 Perf YTD-12.00%
Dividend- P/FCF- EPS past 5Y-16.00% ROI- 52W High-54.57% Beta-1.67
Dividend %- Quick Ratio2.40 Sales past 5Y-34.50% Gross Margin- 52W Low1.99% ATR0.09
Employees97 Current Ratio2.40 Sales Q/Q333.30% Oper. Margin- RSI (14)36.13 Volatility4.38% 5.57%
OptionableYes Debt/Eq0.00 EPS Q/Q-77.70% Profit Margin- Rel Volume0.80 Prev Close1.56
ShortableYes LT Debt/Eq0.00 EarningsMay 06 AMC Payout- Avg Volume2.64M Price1.54
Recom1.70 SMA20-8.78% SMA50-14.51% SMA200-23.30% Volume2,117,980 Change-1.28%
Jun-25-20Initiated BofA/Merrill Buy $5
Aug-26-19Initiated Dawson James Buy $11
Feb-13-18Reiterated Maxim Group Buy $12 → $6
Aug-10-17Reiterated Maxim Group Buy $9 → $12
Feb-07-17Initiated Needham Buy $7
Mar-11-16Reiterated Maxim Group Buy $5 → $10
Jul-09-15Downgrade Piper Jaffray Overweight → Neutral
Jan-23-15Reiterated Maxim Group Buy $7 → $9
Apr-28-14Reiterated Maxim Group Buy $10 → $7
Dec-19-13Reiterated Maxim Group Buy $6 → $10
Oct-05-12Reiterated Maxim Group Buy $3 → $6
May-31-12Initiated Maxim Group Buy $3
Sep-13-10Reiterated WBB Securities Strong Buy $8 → $9
Jul-30-10Upgrade WBB Securities Buy → Strong Buy $8
Apr-12-10Initiated Brean Murray Buy $8
Nov-11-08Reiterated Leerink Swann Outperform $8 → $4
Sep-17-08Initiated Leerink Swann Outperform $8
Aug-01-08Initiated Canaccord Adams Buy $6
Jun-19-08Initiated Lazard Capital Buy $7
Jun-02-08Initiated Cowen & Co Outperform
May-07-21 01:01AM  
May-06-21 04:05PM  
Apr-28-21 01:00PM  
Apr-21-21 12:00PM  
Apr-13-21 07:00AM  
Apr-01-21 07:00AM  
Mar-31-21 03:45PM  
06:00AM  
Mar-27-21 03:45AM  
Mar-25-21 09:00PM  
04:05PM  
Mar-02-21 07:00AM  
Feb-16-21 07:50AM  
07:00AM  
Jan-28-21 08:04AM  
Jan-08-21 08:32AM  
Dec-21-20 03:41PM  
06:00AM  
Dec-02-20 03:48PM  
Nov-16-20 06:00AM  
Nov-14-20 07:39AM  
Nov-11-20 06:00PM  
05:20AM  
Nov-09-20 04:05PM  
Nov-05-20 06:05AM  
Oct-08-20 01:17PM  
Sep-29-20 08:53AM  
Sep-24-20 01:29PM  
Sep-23-20 09:57AM  
06:00AM  
Aug-11-20 02:00AM  
Aug-10-20 04:00PM  
Aug-07-20 08:58AM  
Jul-20-20 02:00PM  
Jun-25-20 10:10AM  
Jun-22-20 02:54PM  
Jun-12-20 08:47AM  
Jun-09-20 05:41PM  
Jun-02-20 01:45PM  
May-18-20 06:00AM  
May-09-20 10:01PM  
May-07-20 04:05PM  
04:00PM  
01:44PM  
May-06-20 02:32PM  
May-05-20 06:00AM  
May-04-20 11:19AM  
May-01-20 06:00AM  
Apr-29-20 02:47PM  
Apr-28-20 06:40AM  
Apr-22-20 12:00AM  
Apr-21-20 08:00AM  
Apr-20-20 04:05PM  
Apr-15-20 09:33PM  
04:27PM  
11:47AM  
08:03AM  
Apr-14-20 08:37AM  
Apr-13-20 09:54AM  
08:03AM  
06:14AM  
06:00AM  
Mar-30-20 06:00AM  
Mar-26-20 10:15AM  
Mar-19-20 06:00AM  
Mar-16-20 04:05PM  
02:30PM  
Mar-09-20 09:58AM  
Feb-10-20 08:00AM  
Feb-03-20 06:00AM  
Jan-24-20 05:36AM  
Jan-15-20 08:22AM  
06:00AM  
Jan-14-20 06:00AM  
Dec-19-19 04:56PM  
Nov-25-19 11:22PM  
Nov-14-19 06:00AM  
Nov-11-19 09:30AM  
Nov-06-19 04:05PM  
Nov-03-19 07:47AM  
Oct-14-19 01:00PM  
Sep-25-19 08:00AM  
Sep-19-19 08:37AM  
Sep-05-19 11:22AM  
Aug-08-19 11:23AM  
Aug-07-19 04:05PM  
Jul-31-19 02:32PM  
Jul-08-19 11:00AM  
Jun-20-19 09:58AM  
Jun-13-19 08:01AM  
Jun-04-19 06:00AM  
May-28-19 06:00AM  
May-24-19 01:46PM  
May-20-19 12:15PM  
May-18-19 09:50AM  
May-14-19 03:54PM  
May-09-19 11:23AM  
May-08-19 04:05PM  
02:30PM  
Apr-23-19 04:08PM  
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lehmann William JRInterim CEOMar 18Sale1.9125,00047,742418,836Mar 18 05:17 PM
Campbell Laura KSenior Vice Pres FinanceMar 16Sale1.9710,00019,655403,692Mar 17 06:26 PM
Harrington John JExec Vice Pres and CSOMar 16Sale2.015,00010,074735,795Mar 17 06:29 PM
Harrington John JExec Vice Pres and CSOMar 15Sale1.975,0009,841740,795Mar 17 06:29 PM
Lehmann William JRPresident and COODec 18Sale2.0220,00040,424457,100Dec 18 05:46 PM
Campbell Laura KSenior Vice Pres FinanceDec 15Sale1.9210,00019,216432,175Dec 17 08:34 PM
Lehmann William JRPresident and COOSep 18Sale2.0420,00040,764490,525Sep 18 05:30 PM
Harrington John JExec Vice Pres and CSOSep 16Sale2.155,00010,761777,718Sep 17 06:16 PM
Harrington John JExec Vice Pres and CSOSep 15Sale2.215,00011,032782,718Sep 17 06:16 PM
TRAUB KENNETH HDirectorJun 24Buy2.2250,000110,900235,093Jun 24 05:09 PM
TRAUB KENNETH HDirectorJun 23Buy2.3150,000115,600185,093Jun 24 05:09 PM
TRAUB KENNETH HDirectorJun 22Buy2.4040,00096,000135,093Jun 24 05:09 PM
Lehmann William JRPresident and COOJun 18Sale2.8620,00057,176524,053Jun 18 08:42 PM